Journal of neurology · 2026
The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dimitriadou Evangelia Makrina, Tzanetakos Dimitrios, Theodorou Aikaterini, Akrivaki Alexandra, Papadopoulos Dimitrios, Mastorodemos Vasileios, Maleska Aleksandra, Sotirli Stefania Alexia, Fakas Nikolaos, Stergiou Christos, Kitsos Dimitrios, Giannopapas Vasileios, Moschovos Christos, Giannopoulos Sotirios, Kuhle Jens, Tsivgoulis Georgios, Tzartos John S
Аннотация
BACKGROUND: Serum neurofilament light chain (sNfL) has emerged as a biomarker reflecting neuroaxonal damage. The role of sNfL in predicting clinical outcome and guiding therapeutic management in multiple sclerosis (MS) is an ongoing research topic. We sought to evaluate sNfL utility for the prediction of achieving No Evidence of Disease Activity-3 (NEDA-3) among MS patients.
METHODS: We conducted a prospective cohort study including MS patients with a single sNfL measurement at first clinical evaluation. Follow-up was performed every 6 months/clinical relapse and included clinical and MRI evaluation. The main outcome was NEDA-3 achievement during follow-up. sNfL levels were measured, using single-molecule-array (SIMOA) assay. sNfL age- and BMI-normalized Z-scores > 1.5 were defined as high. Linear regression analyses were performed to identify predictors of baseline sNfL Z-score and multivariable Cox proportional hazard regression models were used to evaluate predefined outcomes.
RESULTS: We included 125 patients [age at sNfL measurement:40 ± 12, 30% men, 82% relapsing-remitting and 18% progressive MS]:37 treatment-naïve patients, 88 patients under Disease-Modifying-Treatment (DMT) with 19.1 (Interquartile Range:12.1-24.5) months median follow-up. Prior DMT use [β:-0.93; 95%CI:-1.48- -0.38 p-value:0.001] was negatively associated with baseline sNfL Z-scores. Gadolinium-enhancing lesions were associated with higher sNfL Z-scores [adjusted standardized linear regression coefficient-β:0.68; 95%CI:0.03-1.32; p-value:0.036], contrary to T2-weighted lesion activity (β:0.40; 95%CI:0.17-0.94; p-value:0.232). In treatment-naive patients, high sNfL Z-scores were associated with lower probability of achieving NEDA-3 during follow-up [hazard-ratio:0.35; 95%CI:0.13-0.96; p-value:0.041].
CONCLUSIONS: This study demonstrated that gadolinium-enhancing lesions, indicative of active inflammation, are associated with elevated sNfL Z-scores, contrary to T2-weighted lesion-activity and highlights the prognostic value of sNfL in achieving NEDA-3 in treatment-naive patients.
METHODS: We conducted a prospective cohort study including MS patients with a single sNfL measurement at first clinical evaluation. Follow-up was performed every 6 months/clinical relapse and included clinical and MRI evaluation. The main outcome was NEDA-3 achievement during follow-up. sNfL levels were measured, using single-molecule-array (SIMOA) assay. sNfL age- and BMI-normalized Z-scores > 1.5 were defined as high. Linear regression analyses were performed to identify predictors of baseline sNfL Z-score and multivariable Cox proportional hazard regression models were used to evaluate predefined outcomes.
RESULTS: We included 125 patients [age at sNfL measurement:40 ± 12, 30% men, 82% relapsing-remitting and 18% progressive MS]:37 treatment-naïve patients, 88 patients under Disease-Modifying-Treatment (DMT) with 19.1 (Interquartile Range:12.1-24.5) months median follow-up. Prior DMT use [β:-0.93; 95%CI:-1.48- -0.38 p-value:0.001] was negatively associated with baseline sNfL Z-scores. Gadolinium-enhancing lesions were associated with higher sNfL Z-scores [adjusted standardized linear regression coefficient-β:0.68; 95%CI:0.03-1.32; p-value:0.036], contrary to T2-weighted lesion activity (β:0.40; 95%CI:0.17-0.94; p-value:0.232). In treatment-naive patients, high sNfL Z-scores were associated with lower probability of achieving NEDA-3 during follow-up [hazard-ratio:0.35; 95%CI:0.13-0.96; p-value:0.041].
CONCLUSIONS: This study demonstrated that gadolinium-enhancing lesions, indicative of active inflammation, are associated with elevated sNfL Z-scores, contrary to T2-weighted lesion-activity and highlights the prognostic value of sNfL in achieving NEDA-3 in treatment-naive patients.